Review



stellux® chemi human c-peptide elisa kit  (ALPCO)


Bioz Verified Symbol ALPCO is a verified supplier
Bioz Manufacturer Symbol ALPCO manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    ALPCO stellux® chemi human c-peptide elisa kit
    Stellux® Chemi Human C Peptide Elisa Kit, supplied by ALPCO, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stellux® chemi human c-peptide elisa kit/product/ALPCO
    Average 90 stars, based on 1 article reviews
    stellux® chemi human c-peptide elisa kit - by Bioz Stars, 2026-02
    90/100 stars

    Images



    Similar Products

    human b type natriuretic peptide bnp elisa kit  (Thermo Fisher)
    95
    Thermo Fisher human b type natriuretic peptide bnp elisa kit
    Model Structure of the Combinatorial Effects of DOX and TmAb on AC16 Cells. The model is divided into three primary components: (1) Protein Dynamics Model for Apoptosis: This segment includes the Caspase‐9 (Cas9S, Cas9 1–2 ) and Caspase‐3 (Cas 1–3 ) compartments, with Cas9 2 and Cas3 3 (indicated by green circles) representing the measured apoptotic protein responses to the individual and combined effects of DOX and TmAb. (2) Cardiomyocyte Injury Biomarker Model: This model features compartments for B‐type <t>natriuretic</t> peptide <t>(BNP</t> 1–3 ), with BNP 3 (marked by an orange circle) as the key biomarker indicating cardiotoxicity in response to both single‐agent and combinatorial treatments of DOX and TmAb. (3) Cardiomyocyte‐Death Model: This model incorporates two transit compartments (Tr 1–2 ) associated with the Cas3 3 response, which affects the viability compartment (R). Compartment R reflects the relative viability of AC16 cells under DOX and TmAb treatments, alone and in combination. The parameters k cas9 , k cas3 , k bnp , k Tr , and k g , represent first‐order rate constants for the respective responses within their corresponding transit compartments. The parameter kd1 captures the cell death dynamics related to Cas3 3 influencing the viability compartment R , while kd2 defines the inhibition slope of cell growth due to DOX. Detailed descriptions of all parameters are provided in Table .
    Human B Type Natriuretic Peptide Bnp Elisa Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human b type natriuretic peptide bnp elisa kit/product/Thermo Fisher
    Average 95 stars, based on 1 article reviews
    human b type natriuretic peptide bnp elisa kit - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    human genlisa elisa kits  (Krishgen Biosystems)
    94
    Krishgen Biosystems human genlisa elisa kits
    Model Structure of the Combinatorial Effects of DOX and TmAb on AC16 Cells. The model is divided into three primary components: (1) Protein Dynamics Model for Apoptosis: This segment includes the Caspase‐9 (Cas9S, Cas9 1–2 ) and Caspase‐3 (Cas 1–3 ) compartments, with Cas9 2 and Cas3 3 (indicated by green circles) representing the measured apoptotic protein responses to the individual and combined effects of DOX and TmAb. (2) Cardiomyocyte Injury Biomarker Model: This model features compartments for B‐type <t>natriuretic</t> peptide <t>(BNP</t> 1–3 ), with BNP 3 (marked by an orange circle) as the key biomarker indicating cardiotoxicity in response to both single‐agent and combinatorial treatments of DOX and TmAb. (3) Cardiomyocyte‐Death Model: This model incorporates two transit compartments (Tr 1–2 ) associated with the Cas3 3 response, which affects the viability compartment (R). Compartment R reflects the relative viability of AC16 cells under DOX and TmAb treatments, alone and in combination. The parameters k cas9 , k cas3 , k bnp , k Tr , and k g , represent first‐order rate constants for the respective responses within their corresponding transit compartments. The parameter kd1 captures the cell death dynamics related to Cas3 3 influencing the viability compartment R , while kd2 defines the inhibition slope of cell growth due to DOX. Detailed descriptions of all parameters are provided in Table .
    Human Genlisa Elisa Kits, supplied by Krishgen Biosystems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human genlisa elisa kits/product/Krishgen Biosystems
    Average 94 stars, based on 1 article reviews
    human genlisa elisa kits - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    cgrp elisa kit cgrp human elisa kit  (Cusabio)
    93
    Cusabio cgrp elisa kit cgrp human elisa kit
    Model Structure of the Combinatorial Effects of DOX and TmAb on AC16 Cells. The model is divided into three primary components: (1) Protein Dynamics Model for Apoptosis: This segment includes the Caspase‐9 (Cas9S, Cas9 1–2 ) and Caspase‐3 (Cas 1–3 ) compartments, with Cas9 2 and Cas3 3 (indicated by green circles) representing the measured apoptotic protein responses to the individual and combined effects of DOX and TmAb. (2) Cardiomyocyte Injury Biomarker Model: This model features compartments for B‐type <t>natriuretic</t> peptide <t>(BNP</t> 1–3 ), with BNP 3 (marked by an orange circle) as the key biomarker indicating cardiotoxicity in response to both single‐agent and combinatorial treatments of DOX and TmAb. (3) Cardiomyocyte‐Death Model: This model incorporates two transit compartments (Tr 1–2 ) associated with the Cas3 3 response, which affects the viability compartment (R). Compartment R reflects the relative viability of AC16 cells under DOX and TmAb treatments, alone and in combination. The parameters k cas9 , k cas3 , k bnp , k Tr , and k g , represent first‐order rate constants for the respective responses within their corresponding transit compartments. The parameter kd1 captures the cell death dynamics related to Cas3 3 influencing the viability compartment R , while kd2 defines the inhibition slope of cell growth due to DOX. Detailed descriptions of all parameters are provided in Table .
    Cgrp Elisa Kit Cgrp Human Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cgrp elisa kit cgrp human elisa kit/product/Cusabio
    Average 93 stars, based on 1 article reviews
    cgrp elisa kit cgrp human elisa kit - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    human btype natriuretic peptide bnp elisa kit  (Thermo Fisher)
    94
    Thermo Fisher human btype natriuretic peptide bnp elisa kit
    Model Structure of the Combinatorial Effects of DOX and TmAb on AC16 Cells. The model is divided into three primary components: (1) Protein Dynamics Model for Apoptosis: This segment includes the Caspase‐9 (Cas9S, Cas9 1–2 ) and Caspase‐3 (Cas 1–3 ) compartments, with Cas9 2 and Cas3 3 (indicated by green circles) representing the measured apoptotic protein responses to the individual and combined effects of DOX and TmAb. (2) Cardiomyocyte Injury Biomarker Model: This model features compartments for B‐type <t>natriuretic</t> peptide <t>(BNP</t> 1–3 ), with BNP 3 (marked by an orange circle) as the key biomarker indicating cardiotoxicity in response to both single‐agent and combinatorial treatments of DOX and TmAb. (3) Cardiomyocyte‐Death Model: This model incorporates two transit compartments (Tr 1–2 ) associated with the Cas3 3 response, which affects the viability compartment (R). Compartment R reflects the relative viability of AC16 cells under DOX and TmAb treatments, alone and in combination. The parameters k cas9 , k cas3 , k bnp , k Tr , and k g , represent first‐order rate constants for the respective responses within their corresponding transit compartments. The parameter kd1 captures the cell death dynamics related to Cas3 3 influencing the viability compartment R , while kd2 defines the inhibition slope of cell growth due to DOX. Detailed descriptions of all parameters are provided in Table .
    Human Btype Natriuretic Peptide Bnp Elisa Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human btype natriuretic peptide bnp elisa kit/product/Thermo Fisher
    Average 94 stars, based on 1 article reviews
    human btype natriuretic peptide bnp elisa kit - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    human c-peptide elisa kit  (Mercodia Inc)
    90
    Mercodia Inc human c-peptide elisa kit
    Model Structure of the Combinatorial Effects of DOX and TmAb on AC16 Cells. The model is divided into three primary components: (1) Protein Dynamics Model for Apoptosis: This segment includes the Caspase‐9 (Cas9S, Cas9 1–2 ) and Caspase‐3 (Cas 1–3 ) compartments, with Cas9 2 and Cas3 3 (indicated by green circles) representing the measured apoptotic protein responses to the individual and combined effects of DOX and TmAb. (2) Cardiomyocyte Injury Biomarker Model: This model features compartments for B‐type <t>natriuretic</t> peptide <t>(BNP</t> 1–3 ), with BNP 3 (marked by an orange circle) as the key biomarker indicating cardiotoxicity in response to both single‐agent and combinatorial treatments of DOX and TmAb. (3) Cardiomyocyte‐Death Model: This model incorporates two transit compartments (Tr 1–2 ) associated with the Cas3 3 response, which affects the viability compartment (R). Compartment R reflects the relative viability of AC16 cells under DOX and TmAb treatments, alone and in combination. The parameters k cas9 , k cas3 , k bnp , k Tr , and k g , represent first‐order rate constants for the respective responses within their corresponding transit compartments. The parameter kd1 captures the cell death dynamics related to Cas3 3 influencing the viability compartment R , while kd2 defines the inhibition slope of cell growth due to DOX. Detailed descriptions of all parameters are provided in Table .
    Human C Peptide Elisa Kit, supplied by Mercodia Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human c-peptide elisa kit/product/Mercodia Inc
    Average 90 stars, based on 1 article reviews
    human c-peptide elisa kit - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    human elisa kits c-peptide  (Mercodia Inc)
    90
    Mercodia Inc human elisa kits c-peptide
    Model Structure of the Combinatorial Effects of DOX and TmAb on AC16 Cells. The model is divided into three primary components: (1) Protein Dynamics Model for Apoptosis: This segment includes the Caspase‐9 (Cas9S, Cas9 1–2 ) and Caspase‐3 (Cas 1–3 ) compartments, with Cas9 2 and Cas3 3 (indicated by green circles) representing the measured apoptotic protein responses to the individual and combined effects of DOX and TmAb. (2) Cardiomyocyte Injury Biomarker Model: This model features compartments for B‐type <t>natriuretic</t> peptide <t>(BNP</t> 1–3 ), with BNP 3 (marked by an orange circle) as the key biomarker indicating cardiotoxicity in response to both single‐agent and combinatorial treatments of DOX and TmAb. (3) Cardiomyocyte‐Death Model: This model incorporates two transit compartments (Tr 1–2 ) associated with the Cas3 3 response, which affects the viability compartment (R). Compartment R reflects the relative viability of AC16 cells under DOX and TmAb treatments, alone and in combination. The parameters k cas9 , k cas3 , k bnp , k Tr , and k g , represent first‐order rate constants for the respective responses within their corresponding transit compartments. The parameter kd1 captures the cell death dynamics related to Cas3 3 influencing the viability compartment R , while kd2 defines the inhibition slope of cell growth due to DOX. Detailed descriptions of all parameters are provided in Table .
    Human Elisa Kits C Peptide, supplied by Mercodia Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human elisa kits c-peptide/product/Mercodia Inc
    Average 90 stars, based on 1 article reviews
    human elisa kits c-peptide - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    human-specific c-peptide elisa kit  (Mercodia Inc)
    90
    Mercodia Inc human-specific c-peptide elisa kit
    Model Structure of the Combinatorial Effects of DOX and TmAb on AC16 Cells. The model is divided into three primary components: (1) Protein Dynamics Model for Apoptosis: This segment includes the Caspase‐9 (Cas9S, Cas9 1–2 ) and Caspase‐3 (Cas 1–3 ) compartments, with Cas9 2 and Cas3 3 (indicated by green circles) representing the measured apoptotic protein responses to the individual and combined effects of DOX and TmAb. (2) Cardiomyocyte Injury Biomarker Model: This model features compartments for B‐type <t>natriuretic</t> peptide <t>(BNP</t> 1–3 ), with BNP 3 (marked by an orange circle) as the key biomarker indicating cardiotoxicity in response to both single‐agent and combinatorial treatments of DOX and TmAb. (3) Cardiomyocyte‐Death Model: This model incorporates two transit compartments (Tr 1–2 ) associated with the Cas3 3 response, which affects the viability compartment (R). Compartment R reflects the relative viability of AC16 cells under DOX and TmAb treatments, alone and in combination. The parameters k cas9 , k cas3 , k bnp , k Tr , and k g , represent first‐order rate constants for the respective responses within their corresponding transit compartments. The parameter kd1 captures the cell death dynamics related to Cas3 3 influencing the viability compartment R , while kd2 defines the inhibition slope of cell growth due to DOX. Detailed descriptions of all parameters are provided in Table .
    Human Specific C Peptide Elisa Kit, supplied by Mercodia Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human-specific c-peptide elisa kit/product/Mercodia Inc
    Average 90 stars, based on 1 article reviews
    human-specific c-peptide elisa kit - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    stellux® chemi human c-peptide elisa kit  (ALPCO)
    90
    ALPCO stellux® chemi human c-peptide elisa kit
    Model Structure of the Combinatorial Effects of DOX and TmAb on AC16 Cells. The model is divided into three primary components: (1) Protein Dynamics Model for Apoptosis: This segment includes the Caspase‐9 (Cas9S, Cas9 1–2 ) and Caspase‐3 (Cas 1–3 ) compartments, with Cas9 2 and Cas3 3 (indicated by green circles) representing the measured apoptotic protein responses to the individual and combined effects of DOX and TmAb. (2) Cardiomyocyte Injury Biomarker Model: This model features compartments for B‐type <t>natriuretic</t> peptide <t>(BNP</t> 1–3 ), with BNP 3 (marked by an orange circle) as the key biomarker indicating cardiotoxicity in response to both single‐agent and combinatorial treatments of DOX and TmAb. (3) Cardiomyocyte‐Death Model: This model incorporates two transit compartments (Tr 1–2 ) associated with the Cas3 3 response, which affects the viability compartment (R). Compartment R reflects the relative viability of AC16 cells under DOX and TmAb treatments, alone and in combination. The parameters k cas9 , k cas3 , k bnp , k Tr , and k g , represent first‐order rate constants for the respective responses within their corresponding transit compartments. The parameter kd1 captures the cell death dynamics related to Cas3 3 influencing the viability compartment R , while kd2 defines the inhibition slope of cell growth due to DOX. Detailed descriptions of all parameters are provided in Table .
    Stellux® Chemi Human C Peptide Elisa Kit, supplied by ALPCO, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stellux® chemi human c-peptide elisa kit/product/ALPCO
    Average 90 stars, based on 1 article reviews
    stellux® chemi human c-peptide elisa kit - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    human c-peptide enzyme-linked immunosorbent assay (elisa) kit  (DRG Instruments GmbH)
    90
    DRG Instruments GmbH human c-peptide enzyme-linked immunosorbent assay (elisa) kit
    Model Structure of the Combinatorial Effects of DOX and TmAb on AC16 Cells. The model is divided into three primary components: (1) Protein Dynamics Model for Apoptosis: This segment includes the Caspase‐9 (Cas9S, Cas9 1–2 ) and Caspase‐3 (Cas 1–3 ) compartments, with Cas9 2 and Cas3 3 (indicated by green circles) representing the measured apoptotic protein responses to the individual and combined effects of DOX and TmAb. (2) Cardiomyocyte Injury Biomarker Model: This model features compartments for B‐type <t>natriuretic</t> peptide <t>(BNP</t> 1–3 ), with BNP 3 (marked by an orange circle) as the key biomarker indicating cardiotoxicity in response to both single‐agent and combinatorial treatments of DOX and TmAb. (3) Cardiomyocyte‐Death Model: This model incorporates two transit compartments (Tr 1–2 ) associated with the Cas3 3 response, which affects the viability compartment (R). Compartment R reflects the relative viability of AC16 cells under DOX and TmAb treatments, alone and in combination. The parameters k cas9 , k cas3 , k bnp , k Tr , and k g , represent first‐order rate constants for the respective responses within their corresponding transit compartments. The parameter kd1 captures the cell death dynamics related to Cas3 3 influencing the viability compartment R , while kd2 defines the inhibition slope of cell growth due to DOX. Detailed descriptions of all parameters are provided in Table .
    Human C Peptide Enzyme Linked Immunosorbent Assay (Elisa) Kit, supplied by DRG Instruments GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human c-peptide enzyme-linked immunosorbent assay (elisa) kit/product/DRG Instruments GmbH
    Average 90 stars, based on 1 article reviews
    human c-peptide enzyme-linked immunosorbent assay (elisa) kit - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Model Structure of the Combinatorial Effects of DOX and TmAb on AC16 Cells. The model is divided into three primary components: (1) Protein Dynamics Model for Apoptosis: This segment includes the Caspase‐9 (Cas9S, Cas9 1–2 ) and Caspase‐3 (Cas 1–3 ) compartments, with Cas9 2 and Cas3 3 (indicated by green circles) representing the measured apoptotic protein responses to the individual and combined effects of DOX and TmAb. (2) Cardiomyocyte Injury Biomarker Model: This model features compartments for B‐type natriuretic peptide (BNP 1–3 ), with BNP 3 (marked by an orange circle) as the key biomarker indicating cardiotoxicity in response to both single‐agent and combinatorial treatments of DOX and TmAb. (3) Cardiomyocyte‐Death Model: This model incorporates two transit compartments (Tr 1–2 ) associated with the Cas3 3 response, which affects the viability compartment (R). Compartment R reflects the relative viability of AC16 cells under DOX and TmAb treatments, alone and in combination. The parameters k cas9 , k cas3 , k bnp , k Tr , and k g , represent first‐order rate constants for the respective responses within their corresponding transit compartments. The parameter kd1 captures the cell death dynamics related to Cas3 3 influencing the viability compartment R , while kd2 defines the inhibition slope of cell growth due to DOX. Detailed descriptions of all parameters are provided in Table .

    Journal: CPT: Pharmacometrics & Systems Pharmacology

    Article Title: Mitigating Trastuzumab‐Doxorubicin Cardiotoxicity With Multiscale Quantitative Systems Toxicology and PBPK‐Toxicodynamic Predictive Modeling Framework

    doi: 10.1002/psp4.70087

    Figure Lengend Snippet: Model Structure of the Combinatorial Effects of DOX and TmAb on AC16 Cells. The model is divided into three primary components: (1) Protein Dynamics Model for Apoptosis: This segment includes the Caspase‐9 (Cas9S, Cas9 1–2 ) and Caspase‐3 (Cas 1–3 ) compartments, with Cas9 2 and Cas3 3 (indicated by green circles) representing the measured apoptotic protein responses to the individual and combined effects of DOX and TmAb. (2) Cardiomyocyte Injury Biomarker Model: This model features compartments for B‐type natriuretic peptide (BNP 1–3 ), with BNP 3 (marked by an orange circle) as the key biomarker indicating cardiotoxicity in response to both single‐agent and combinatorial treatments of DOX and TmAb. (3) Cardiomyocyte‐Death Model: This model incorporates two transit compartments (Tr 1–2 ) associated with the Cas3 3 response, which affects the viability compartment (R). Compartment R reflects the relative viability of AC16 cells under DOX and TmAb treatments, alone and in combination. The parameters k cas9 , k cas3 , k bnp , k Tr , and k g , represent first‐order rate constants for the respective responses within their corresponding transit compartments. The parameter kd1 captures the cell death dynamics related to Cas3 3 influencing the viability compartment R , while kd2 defines the inhibition slope of cell growth due to DOX. Detailed descriptions of all parameters are provided in Table .

    Article Snippet: Essential assay kits included BCA protein assay, protease inhibitor cocktail, human cardiac troponin I ELISA kit, and human B‐type natriuretic peptide (BNP) ELISA kit from Thermo Fisher Scientific (Waltham, MA).

    Techniques: Biomarker Discovery, Inhibition